Robert J. Motzer

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4058

Top 20%

1.0DataRank

Top 20%23 citations

Renzo G. DiNatale, Phillip M. Rappold, Christopher J. Fong, Francisco Sánchez-Vega, Andrew W. Silagy +15 more

Papers

Driven by 64 papers — median percentile 40. Top paper: “Improved prediction of immune checkpoint blockade efficacy across multiple cancer types”.

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

Nature Biotechnology(2021)10.1038/s41587-021-01070-8

N/A

7.3DataRank · unranked

272 citations

Seong‐Keun Yoo, Cristina Valero, Alessandro Pastore, Chirag Krishna, Mark Lee +29 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079

N/A

6.4DataRank · unranked

524 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +15 more

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00241-2

N/A

5.2DataRank · unranked

186 citations

Amishi Y. Shah, Drew Rasco, Arpit Rao, Matthew H. Taylor, Christopher Di Simone +23 more

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005445

N/A

2.7DataRank · unranked

69 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Saby George +9 more

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology(2021)10.1016/j.eururo.2021.10.001

N/A

2.6DataRank · unranked

80 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +17 more

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

ESMO Open(2024)10.1016/j.esmoop.2024.102994

N/A

1.9DataRank · unranked

94 citations

Mauricio Burotto, Bernard Escudier, Andrea B. Apolo, María T. Bourlon, Amishi Y. Shah +15 more

Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3283

N/A

1.9DataRank · unranked

55 citations

Renzo G. DiNatale, Alejandro Sánchez, Ritesh R. Kotecha, Sounak Gupta, Fengshen Kuo +18 more

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Cancer(2020)10.1002/cncr.33148

N/A

1.2DataRank · unranked

38 citations

Yasser Ged, Chung‐Han Lee, Andrea Knežević, Ana M. Molina, Ying‐Bei Chen +13 more

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-21-0053

N/A

1.2DataRank · unranked

33 citations

Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero +21 more

Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4058

Top 20%

1.0DataRank

Top 20%23 citations

Renzo G. DiNatale, Phillip M. Rappold, Christopher J. Fong, Francisco Sánchez-Vega, Andrew W. Silagy +15 more

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Cell(2022)10.1016/j.cell.2022.01.003

N/A

0.973DataRank · unranked

654 citations

Christopher J. Fong, Anisha Luthra, Shaleigh Smith, Renzo G. DiNatale, Subhiksha Nandakumar +70 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0.875DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas

European Urology Focus(2022)10.1016/j.euf.2021.12.002

N/A

0.835DataRank · unranked

27 citations

Cerise Tang, Mark Zucker, Kelly N. Fitzgerald, Renzo G. DiNatale, Phillip M. Rappold +15 more

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial

European Journal of Cancer(2022)10.1016/j.ejca.2022.09.020

N/A

0.795DataRank · unranked

18 citations

Thomas Powles, Bernard Escudier, Mauricio Burotto, Joshua Zhang, Burçin Şimşek +4 more

Testicular Cancer, Version 2.2015

Journal of the National Comprehensive Cancer Network(2015)10.6004/jnccn.2015.0092

N/A

0.732DataRank · unranked

131 citations

Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger +27 more

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial

Annals of Oncology(2025)10.1016/j.annonc.2025.09.006

N/A

0.719DataRank · unranked

18 citations

Bernard Escudier, Mauricio Burotto, Thomas Powles, Andrea B. Apolo, María T. Bourlon +16 more

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine

Nature Immunology(2022)10.1038/s41590-022-01274-3

N/A

0.663DataRank · unranked

82 citations

David A. Knorr, Laura A. Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A. Apostolidis +23 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0.609DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5023

N/A

0.599DataRank · unranked

12 citations

Opeyemi A. Jegede, Miriam Sant’Angelo, Sonia Moreno, David A. Braun, Megan Wind‐Rotolo +15 more

Immune-Related Colitis Is Associated with Fecal Microbial Dysbiosis and Can Be Mitigated by Fecal Microbiota Transplantation

Cancer Immunology Research(2023)10.1158/2326-6066.cir-23-0498

N/A

0.564DataRank · unranked

42 citations

Nicholas R. Waters, Natalie Smith, Anqi Dai, John Slingerland, Nathan Aleynick +24 more

Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease

Journal of Clinical Oncology(2024)10.1200/jco.23.02542

N/A

0.556DataRank · unranked

14 citations

Andrea Knežević, Maria Bromberg, Sujata Patil, Joel Sheinfeld, Brett S. Carver +9 more

Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial

European Urology(2024)10.1016/j.eururo.2024.04.025

N/A

0.542DataRank · unranked

36 citations

Chung-Han Lee, Martin H. Voss, Maria I. Carlo, Andrea Knezevic, Laura Peralta +11 more

Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.5_suppl.437

N/A

0.497DataRank · unranked

14 citations

Sai Vikram Vemula, Robert J. Motzer, Aparna Chhibber, Deepthi Chowbene, Nahuel Perrot +7 more

Immunometabolic coevolution defines unique microenvironmental niches in ccRCC

Cell Metabolism(2023)10.1016/j.cmet.2023.06.005

N/A

0.483DataRank · unranked

24 citations

Amy Xie, Eric Minwei Liu, Fengshen Kuo, Min‐Soo Kim, Renzo G. DiNatale +15 more

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.10.017

N/A

0.416DataRank · unranked

15 citations

Sahil D. Doshi, Andrea Knežević, Joshua Chaim, Ying‐Bei Chen, Rachel Jacobi +14 more

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma

European Urology Open Science(2021)10.1016/j.euros.2021.06.008

N/A

0.241DataRank · unranked

4 citations

Yin Wan, Alan D. Smith, Ran Xie, Robert J. Motzer, Chung‐Han Lee

Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone

Urologic Oncology Seminars and Original Investigations(2025)10.1016/j.urolonc.2025.08.004

N/A

0.104DataRank · unranked

1 citations

Mark Dawidek, Andrea Knežević, Marc Ganz, Lina Posada, Yash S. Khandwala +13 more

An evaluation of the role of tumor load in cytoreductive nephrectomy

Canadian Urological Association Journal(2020)10.5489/cuaj.6350

N/A

0.104DataRank · unranked

1 citations

Cihan Düzgöl, Julian Marcon, Renzo G. DiNatale, Roy Mano, Kyle A. Blum +8 more

A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma

European Urology Oncology(2025)10.1016/j.euo.2025.03.010

N/A

0.104DataRank · unranked

1 citations

Sahil D. Doshi, Andrea Knežević, Rachel Jacobi, Hyung Jun Woo, David H. Aggen +13 more

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2274

N/A

0DataRank · unranked

37 citations

Opeyemi A. Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J. West, Emily Walton +16 more

A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma

Cancer Discovery(2022)10.1158/2159-8290.cd-21-0925

N/A

0DataRank · unranked

33 citations

Lynda Vuong, Josef Leibold, Nicholas H. Chakiryan, Michael Curry, Fengshen Kuo +31 more

Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.100947

N/A

0DataRank · unranked

27 citations

Evan J. Lipson, Ludmila Danilova, Suzanne L. Topalian, Jaroslaw Jedrych, Ezra Baraban +10 more

Evaluation of germline genetic testing criteria in early-onset kidney cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.296

N/A

0DataRank · unranked

0 citations

Rania Sheikh, Ritesh R. Kotecha, Yelena Kemel, Aliya Khurram, Peter A. Reisz +15 more

Genomic ancestry in kidney cancer: Correlations with clinical and molecular features

Cancer(2023)10.1002/cncr.35074

N/A

0DataRank · unranked

12 citations

Andrea Knežević, Kanika Arora, Chaitanya Bandlamudi, Fengshen Kuo, Maria I. Carlo +12 more

Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma

Urologic Oncology Seminars and Original Investigations(2023)10.1016/j.urolonc.2023.12.003

N/A

0DataRank · unranked

6 citations

Lennert Eismann, Charlie White, Juan Arroyave Villada, Sari Khaleel, Irina Ostrovnaya +13 more

Localised non‐metastatic sarcomatoid renal cell carcinoma: a 31‐year externally verified study

British Journal of Urology(2023)10.1111/bju.16125

N/A

0DataRank · unranked

7 citations

Andrew W. Silagy, Andrea Knežević, Stanley Weng, Alan Wang, Roy Mano +13 more

Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab

(2023)10.1158/1541-7786.c.6545243

N/A

0DataRank · unranked

2 citations

Renzo G. DiNatale, Diego Chowell, Chirag Krishna, Vladimir Makarov, Cristina Valero +21 more

Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4598

N/A

0DataRank · unranked

2 citations

Neha Ratna, David Gavrilov, Cihan Düzgöl, Mahnoor Akhlaq, Min Yuen Teo +15 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Data from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

(2023)10.1158/1078-0432.c.6532988.v1

N/A

0DataRank · unranked

0 citations

Alejandro Sánchez, Sujata Patil, Andrea Knežević, Emily Stein, Stacey Petruzella +15 more

Data from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

(2023)10.1158/1078-0432.c.6532988

N/A

0DataRank · unranked

0 citations

Alejandro Sánchez, Sujata Patil, Andrea Knežević, Emily Stein, Stacey Petruzella +15 more

Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4559

N/A

0DataRank · unranked

0 citations

Andrew R. Schroeder, Semanti Mukherjee, Yelena Kemel, Ritesh R. Kotecha, Chung‐Han Lee +12 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.323

N/A

0DataRank · unranked

5 citations

Kyrollis Attalla, Sujata Patil, Samuel Murray, Ying‐Bei Chen, Ritesh R. Kotecha +5 more

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes

Cancer Cell(2024)10.1016/j.ccell.2024.03.002

N/A

0DataRank · unranked

46 citations

Chris Labaki, Tejas Jammihal, Wanling Xie, Maxine Sun, Valisha Shah +19 more

Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2020.12.002

N/A

0DataRank · unranked

2 citations

Darren R. Feldman, Michael J. Morris, Robert J. Motzer, Dana E. Rathkopf, Ashley Marie Regazzi +5 more

Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma

Cancer(2021)10.1002/cncr.33790

N/A

0DataRank · unranked

19 citations

Ritesh R. Kotecha, Stanley Weng, Arturo Holmes, Nirmish Singla, Roy Mano +10 more

Gene expression of prostate-specific membrane antigen (FOLH1) in clear cell renal cell carcinoma predicts angiogenesis and response to tyrosine kinase inhibitors

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.10.013

N/A

0DataRank · unranked

6 citations

Marlon Perera, Nathan Papa, Fengshen Kuo, Mahdi Golkaram, Phillip M. Rappold +7 more

Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials

Clinical Genitourinary Cancer(2024)10.1016/j.clgc.2024.102268

N/A

0DataRank · unranked

0 citations

Andrea Knežević, Carlene Gonzalez, Patricia Fischer, ROBERT GOODMAN, Suzanne Gornell +9 more

Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing

European Urology Oncology(2021)10.1016/j.euo.2021.09.005

N/A

0DataRank · unranked

39 citations

Rania Sheikh, Ritesh R. Kotecha, Yelena Kemel, Peter A. Reisz, Andrew T. Lenis +22 more

Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series

The Oncologist(2025)10.1093/oncolo/oyaf208

N/A

0DataRank · unranked

12 citations

Andrea P. Moy, Stephen W. Dusza, Alison J. Moskowitz, Gopa Iyer, Afsheen N. Iqbal +8 more

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors

Annals of Oncology(2025)10.1016/j.annonc.2025.03.002

N/A

0DataRank · unranked

7 citations

Fady Baky, Nicole Liso, B.M. Williams, Sanjay Porwal, Melissa Assel +13 more

Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy

Cancer Cell(2021)10.1016/j.ccell.2021.03.007

N/A

0DataRank · unranked

444 citations

Renzo G. DiNatale, Fengshen Kuo, Raghvendra M. Srivastava, Lynda Vuong, Diego Chowell +28 more

Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma

European Urology Oncology(2025)10.1016/j.euo.2025.11.003

N/A

0DataRank · unranked

1 citations

Stephen W. Reese, Burçin Ağrıdağ Üçpınar, Andrea Knežević, Lennert Eismann, Chih‐Ying Wu +14 more

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Detailed evaluation of hearing loss (HL) associated with high-dose (HD) carboplatin for salvage treatment of germ cell tumors (GCT).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.401

N/A

0DataRank · unranked

1 citations

Andrea Knežević, Kaamilah Wilson, Maria Bromberg, Amy Budnick, Deaglan Joseph McHugh +7 more

Pathologic Response to Immunotherapy is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma

medRxiv(2025)10.1101/2025.04.24.25326353

N/A

0DataRank · unranked

0 citations

Stephen W. Reese, Burçin Ağrıdağ Üçpınar, Andrea Knežević, Lennert Eismann, Chih‐Ying Wu +14 more

Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma

Urologic Oncology Seminars and Original Investigations(2025)10.1016/j.urolonc.2025.08.012

N/A

0DataRank · unranked

0 citations

Daniel Barbakoff, Burçin Ağrıdağ Üçpınar, Andrea Knežević, Kelly Fitzgerald, Lennert Eismann +12 more

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response

Nature Communications(2020)10.1038/s41467-020-17965-0

N/A

0DataRank · unranked

66 citations

Kyrollis Attalla, Renzo G. DiNatale, Irina Ostrovnaya, Jessica Flynn, Kyle A. Blum +12 more

Supplementary Table 4 from Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy

10.1158/1078-0432.22450608

Top 100%

0DataRank

Top 100%0 citations

A. Ari Hakimi, Can G. Pham, A. Rose Brannon, Ying-Bei Chen, Luis F. Cunha +15 more

A robust, trial-agnostic gene signature for response to tyrosine kinase inhibition in ccRRCC.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4558

N/A

0DataRank · unranked

0 citations

Minwei Liu, Fengshen Kuo, Ritesh R. Kotecha, Chung‐Han Lee, Martin H. Voss +4 more

Robert J. Motzer

Indexed papers

Top data-sharing exemplar

Papers